Bsc Biotechnology What Does The Course Cover? – Good Herald

If you are interested in a career in one of the most interesting areas of science then you should consider joining the field of biotechnology. Armed with a BSc Biotechnology degree, you will be able to apply for many interesting and high paying jobs across a number of industries. As a matter of fact, there are quite a few colleges in Dehradun that offer three year graduate programs in biotechnology because there is a great deal of demand for a degree in this field on account of its robust job prospects. Keep in mind that youll generally need to have a background in science (10 + 2) in order to be able to apply for this course because math, biology and chemistry are very important to students in this field.

The field of biotechnology is growing at a very rapid pace and it is also essential to many industries. The importance of this field comes from its ability to use technological methodologies to improve a number of biological systems in order to create new processes and products that have the ability to improve our life overall. The field of biotechnology consists of many different areas of study. Some of the most important ones are Immunology, Molecular Biology, Genetic Engineering, Microbiology and Environmental Biotechnology, just to name a few. Plant and animal biotechnology are also important areas of study.

Since the field of biotechnology is a very vast one that covers many different areas of study, it is best for you to understand which area appeals to you the best before you select a particular program. It is also important to keep in mind that the employment opportunities offered by each area of study differ considerably. Even so, you will find that employment opportunities for a BSc biotechnology graduate are fairly robust.

If you have a BSc Biotechnology degree then you will be able to get employment right away although a Masters degree will brighten your job prospects further. As a graduate, you will be able to get jobs in various fields including chemicals, pharmaceuticals, food processing and agriculture. The government is a very good source of jobs for biotechnologists and so are many large corporate houses. Waste management is a very important area these days and there is great need for biotechnologists who specialize in this area. As you can see, biotechnology is a very large and important field that is worth entering.

For more information on B.Sc Biotechnology. Visit Today http://bfitdoon.com/bsc-biotechnology.php

Photo By OpenClipart-Vectors from Pixabay

Read the original here:
Bsc Biotechnology What Does The Course Cover? - Good Herald

Puma Biotechnology: Shares on the prowl – Times of India

BUZZ-Puma Biotechnology: Shares on the prowl:BUZZ-Puma Biotechnology: Shares on the prowl

** Puma Biotechnology shares soar 50.3 pct to $56.80 in heavy Monday morning trading; shares rise as high as $69.35, halted multiple times for volatility

** U.S. Food and Drug Administration posts documents reviewing Puma's neratinib for treating breast cancer ahead of FDA advisory committee meeting on the product on Weds

** Based on sensitivity analyses conducted, results appear to be generally similar to the primary analysis results, supporting an effect of neratinib, FDA staffers say in review documents

** Options market has been pricing in a move about 63 pct, positive or negative, in PBYI shares in reaction to neratinib review, JPMorgan analyst Cory Kasimov said in research note last week

** Short interest in PBYI shares stood at 21.5 pct of shares outstanding as of Apr 27, according to Thomson Reuters data

** Five analysts rate PBYI shares a "buy" or "strong buy", two rate "hold", according to TR data; median price target is $80

** PBYI shares have nearly doubled in 2017, against 9.7 pct rise for Nasdaq Biotechnology index

(This story has not been edited by timesofindia.com and is autogenerated from a syndicated feed we subscribe to.)

RELATED

StyleBistro

Minivans - Sponsored Ads

Puppytoob

View original post here:
Puma Biotechnology: Shares on the prowl - Times of India

Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology – Equity Research Is Published In The … – Exchange News Direct

Cellect Biotechnology Ltd, based in Israel, has developed an innovative technology which enables the production of stem cells to therapies and treatments that require stem cells as the main raw material. The company trades on both the Tel Aviv Stock Exchange (TASE) and NASDAQ, and had a market capitalisation at TASE of ca. 45 million USD (prior to the release of Frost & Sullivan report today).

Frost & Sullivan publishes equity research reports on technology, biomed and healthcare companies that are listed on the TASE, within the framework of the analysis program that the TASE has initiated. Key goals of the program are enhancing global awareness of these companies and enabling more informed investment decisions by investors interested in hot Israeli hi-tech and healthcare companies.

In the coming months, Frost & Sullivan will release 9 additional initiation coverage reports, covering the other companies that have joined the programme: 6 biomed companies Aposense, Brainsway, BiolineRX, Kitov Pharmaceuticals, D.N.A. Biomedical Solutions, and Redhill Biopharma; and 3 technology companies: Safe-T Group, Vonetize and Energix Renewable Energies.

For the purpose of equity research services, Frost & Sullivan, the leading global consulting, and market research firm, will leverage relevant analysts, experts and growth consultiants among a staff of 1,800, at ca. 50 branches across 6 continents, including in Israel. Frost & Sullivan will utilize the experience and know-how accumulated over the course of 55 years in medical technologies, life sciences, technology, energy, and other industrial fields, including the publication of tens of thousands of market and technology research reports, and economic analyses and valuations.

Starting September 2016 Edison Investment Research released analyses of 11 companies, and a significant increase in trading volume and in the exposure of the companies included in the project to both the local and foreign investing public is evident. It is noteworthy that in most of the reviewed dual listings, trading volume has increased significantly both in Israel and the United States.

See the original post here:
Frost & Sullivan Publishes Initiation Coverage Report On Cellect Biotechnology - Equity Research Is Published In The ... - Exchange News Direct

Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? – Zacks.com

Puma Biotechnology, Inc. (PBYI - Free Report) is expected to report first-quarter 2017 results later this month. The companys earnings track record is disappointing as it missed estimates in three of the trailing four quarters and met expectations in one. The company had an average negative surprise of 3.23% in the last four quarters.

Pumas shares have outperformed the Zacks classified Medical-Biomedical and Genetics industry, year to date. Shares of the company gained 27.2% so far this year, while the industry recorded an increase of 5.5%.

In the last reported quarter, Puma posted a negative surprise of 0.99%. Lets see how things are shaping up for this announcement.

Factors at Play

Being a development-stage company, Puma Biotech does not have any approved product in its portfolio. Thus, investor focus should remain on updates pertaining to the development of neratinib, its lead pipeline candidate.

The candidate is currently under review in both the U.S. and the EU for the extended adjuvant treatment of HER2-positive early-stage breast cancer in patients who have previously been treated with Herceptin-based adjuvant therapy.

Moreover, several phase II combination studies on neratinib for the treatment of breast cancer are currently underway.

In Apr 2017, Puma presented encouraging additional data from breast cancer studies at the San American Association for Cancer Research Annual (AACR) on neratinib. These include interim data from a phase II study in patients with HER2-positive early stage breast cancer who had completed trastuzumab-based adjuvant therapy; interim phase I/II data from the NSABP FB-10 trial of neratinib plus Kadcyla (T-DM1) in HER2-positive MBC; and phase II data from SUMMIT study in HER2-negative breast cancer patients with HER2 mutations.

Puma anticipates more data updates in the second quarter. These include additional data from the phase III study on neratinib in third-line HER2-positive metastatic breast cancer patients and data from a phase II study on neratinib in HER2-positive metastatic breast cancer patients with brain metastases.

Earnings Whispers

Our proven model does not conclusively show that Puma Biotech is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here as you will see below.

Zacks ESP:TheEarnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of $2.08. You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Zacks Rank:Puma Biotechs carries a Zacks Rank #4 (Sell). As it is that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Other Stocks That Warrant a Look

Here are some health care stocks that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this quarter.

Conatus Pharmaceuticals Inc. (CNAT - Free Report) is scheduled to release results on May 4. The company has an Earnings ESP of +57.14% and a Zacks Rank #3. You can seethe complete list of todays Zacks #1 Rank stocks here.

ImmunoGen, Inc. (IMGN - Free Report) is scheduled to release results on May 5. The company has an Earnings ESP of +8.33% and a Zacks Rank #3.

FIBROGEN INC (FGEN - Free Report) is scheduled to release results on May 8. The company has an Earnings ESP of +23.81% and a Zacks Rank #3.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

See the original post:
Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint? - Zacks.com

Cellect Biotechnology Gets European Patent (APOP) – Investopedia

Cellect Biotechnology Gets European Patent (APOP)
Investopedia
secured a European patent covering a method of treatment from the European Patent Office. The patent covers cell-based therapeutics of Cellect's technology and method that have the potential to treat diseases like diabetes, graft-versus-host disease, ...
BRIEF-Cellect Biotechnology receives formal notice of intention to grant for a patent from European patent officeReuters
Cellect Biotechnology (APOP) Granted European Patents Protecting ...StreetInsider.com
Cellect Biotechnology Ltd. (NASDAQ:APOP) reported an European patent grantBenchmark Monitor
GlobeNewswire (press release)
all 9 news articles »

See the original post here:
Cellect Biotechnology Gets European Patent (APOP) - Investopedia

DSM ‘excited’ by biotechnology opportunites, president says – FoodBev.com

The president of DSM Food Specialties, Ilona Haaijer, has told FoodBev that shes really excited to be able to offer laboratory and scale-up facilities as part of its new biotechnology centre in the Netherlands.

The company unveiled the Rosalind Franklin Biotechnology Center on its Delft campus earlier, where more than 400 scientists will advance the companys research into food enzymes, cultures, bio-preservatives and taste ingredients for the global food industry.

Alongside significant investments in robotics and automation, the centre includes space for start-ups to explore and scale up their concepts in partnership with DSM Food Specialties.

At the opening: Alex Clere

There was a general buzz, a sense of excitement at the unveiling of DSMs imposing glass biotechnology centre this morning. DSMs scientists had already moved in, keen to give visitors an impression of the new equipment some the result of millions of euros worth of investment and collaborative spaces in action.

Ahead of the unveiling ceremony, DSM Food Specialties president Ilona Haaijer told me which of the companys products she thought were particularly pertinent, given the state of the food industry at the moment.

Its MaxiLact product, which removes lactose from a product while delivering additional sugar reductions, was flying, she said. And the Preventase proprietary enzyme allows brands to limit the amount of acrylamide in bakery items amid widespread concern across Europe.

This new centre, a major achievement for DSM Food Specialties, will help the business continue to meet the industrys biggest trends and satisfy changes to consumer preference.

The Rosalind Franklin Biotechnology Center is part of DSM Food Specialties network of more than 30 laboratories in ten countries. According to Gerhard Wagner, the director of DSMs Biotechnology Center, the company has sought to align itself with local technology hubs like Boston, Massachusetts and put down roots close to its markets.

Haaijer also noted that the world was becoming an increasingly volatile, uncertain, complex and ambiguous (VUCA) place, which made the prediction of future trends difficult.

The process was no longer as linear as it had once been, becoming an art, not a science.

But in that challenge was the opportunity for DSM to increase its participation with external stakeholders, like Delft University of Technology and Corbion.

The biotechnology centre in Delft has also been designed with the help of DSMs scientists, and includes features and open spaces deliberately intended to encourage cooperation and collaboration between employees.

Haaijer claimed that it was more and more important to open up with chief operating officer Cindy Gerhardt adding that this was the only way companies can be early to market with a product.

The Rosalind Franklin Biotechnology Center will play a crucial role in that strategy.

See the original post:
DSM 'excited' by biotechnology opportunites, president says - FoodBev.com

Impact Of FDA Breakthrough Therapy Designation Speculative Biotechnology Stock Performance – Seeking Alpha

Breakthrough Therapy Designation is described on the FDA website as "a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s)." It was signed into law in 2012, with the first full approval of a breakthrough designation candidate being only one year later. As of March 30, 2017, FDA has granted breakthrough therapy designation to 170 of the 505 total requests, and eventually approved 55 breakthrough therapy designated products.

The concept makes sense. If a new drug that aims to treat serious and life-threatening conditions shows unprecedented effect in early clinical trials, patients should not have to wait to receive treatment. A group called Friends of Cancer Research worked with partners in advocacy, regulation, drug development, and bipartisan congressional champions to take breakthrough therapy designation from concept to an expedited FDA development program. This ensures patient access to revolutionary drugs is as quick and effective as possible. A drug that receives breakthrough therapy designation is eligible for all FDA fast track features, intensive FDA guidance on an efficient development program (as early as phase 1), and organizational commitment involving FDA senior project managers.

FDA bases its decision to grant breakthrough therapy designation on scientific support for clinical endpoint(s). Studies that demonstrate a drug's effect on a surrogate or intermediate clinical endpoint must be "adequate and well controlled" as required by the FD&C Act. Using surrogate or intermediate endpoints can save valuable time in the drug approval process. Consider an example of cancer patients. Rather than wait for a study to complete a potentially lengthy overall survival measurement, FDA may approve a drug based on evidence of tumor shrinkage, associated with a shorter measure such as progression-free survival, because it is considered reasonably likely to predict clinical benefit (and hence prolonged survival of patients).

This well written article about the drug development process addresses the process and is worth a quick read. A cancer drug development company will still need to conduct studies to confirm that tumor shrinkage actually predicts that patients will live longer, which is sometimes a phase 3 or even a phase 4 clinical trial. One common question often asked by StrongBio stock club members (send email to join, its free) is, "will a company have to wait to market a drug until trials assessing secondary endpoint data or confirmational long-term effects of drugs on a patient population are completed"? So the answer can be yes or it can be no. The industry currently anticipates that primary consideration for marketing approval by FDA is primary endpoint result(s). So it depends what the primary endpoint of the trial is predetermined to be with FDA, in an advanced declaration called a special protocol assessment. Though caution is warranted when predicting clinical trial result interpretation by FDA, it is clear that shorter endpoint measures such as progression free survival were specifically developed by scientists and clinicians (over many years with massive resource allocation) as reliable metrics for early approval.

As a biotechnology stock investor, one valuable tool for learning about what therapeutic candidates FDA might favor, is the Friends of Cancer Research list of FDA Breakthrough Therapy Designations. If you have not included this or Knect365 lists as part of your due diligence, please consider doing it now. These lists consist of many indications in medicine, not just cancer. Many, but not all, of the stocks on this list have performed well, and having FDA in a supportive role behind a drug candidate has proven to have boosted confidence in these stocks when reviewed in articles analyzing how they are priced by the Street. Since excitement surrounds the designation, an increased stock price can be used to generate funds for the company to begin early manufacturing initiatives. In this way investors help serve those in need of life-saving therapies by funding faster production in hopes for a future payoff. Everyone can win in this positive scenario.

Genentech [Roche Holdings, (OTCQX:RHHBY)], with 15 breakthrough therapy designations, is a leader in the breakthrough designation category, with several rare and specialty indications. But with its multiple players and large market cap, it's more difficult to measure an effect of a breakthrough therapy on stock price. Factors that an investor should consider when looking at the designation is the potential market compared to company market cap. So Immunomedic's (NASDAQ:IMMU) Sacituzumab Govitecan breakthrough therapy designation for triple negative breast cancer with a 6 billion dollar market and only 600 million dollar market cap might be seen as more attractive in contrast to RHHBY (market cap 216 billion) rituximab designation for pemphigus vulgaris, a rare autoimmune disease causing skin and mucosal membrane blisters, with estimated market in the low hundreds of millions. At the time (February 2016) IMMU reported its breakthrough therapy designation it was trading at about 2 dollars per share, and is now about 6.50 about a year later (after several futile attempts by short-sellers to discredit the company ultimately at breast cancer victim's expense), compared to RHHBY, which has moved from about 31 dollars per share since its Mar 21, 2017 announcement to 32 dollars this week. It is extremely unlikely rituximab will drive RHHBY to 105 dollars one year from now to match IMMU's market performance of Sacituzumab Govitecan. However, one should never underestimate the ability of big pharma to gain an expedited product approval and then have that product used for other indications "off label" when other treatments fail. For instance, rituximab has implications in treating Lupus, with an increasing 3.5 billion dollar industry by 2025. For the purpose of breakthrough therapy designation affecting stock price, StrongBio will focus on a few publicly traded (Novimmune, Rebiotix, and Rhythm are interesting but privately held companies) small market cap representatives in this article in order to make some conclusions, referring to larger market cap companies as a point of reference.

Like IMMU, Adaptimmune (NASDAQ:ADAP) received breakthrough therapy status, but for affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma in February 2016. With a market cap of under 400 million and a potential market in the low hundreds of millions per year in synovial (and other off label or future indication) sarcomas, this is certainly an attractive investment to StrongBio if weakness in market price should occur. Some investors regard ADAP as some of the best cancer work being done right now, and recommends it as a good investment in the 200 billion dollar immunotherapy cancer space. Having raised some funds recently and having strong partners, the stock has decreased in value from about 7 dollars per share to about 5.50, but has some recent positive momentum after raising funds in an offering at just over 4 per share. It was first covered by StrongBio at 4 dollars earlier this year. IMMU and ADAP have both shown to be somewhat volatile following breakthrough therapy designation, warranting scrutiny of timing before entering a long position based upon breakthrough designation.

Another stock, like ADAP, that has trended down since its breakthrough designation by FDA is Trevena (NASDAQ:TRVN). TRVN has dropped over 50% since designation, February 22, 2016, shooting from 7 dollars per share to about 9 dollars per share, but is now trading at 3.65 per share one year later. TRVN's oliceridine, an acute pain control drug for treating moderate to severe post-bunionectomy or abdominoplasty, even met its phase 3 trial endpoints for pain control. But as this article summarizes well, may be seen as too expensive compared to morphine and other pain killers. This article by the Street makes a good case for TRVN in how oliceridine met pain control endpoints and potentially offers an advantage in a profile of side-effects including nausea, vomiting, and depressed breathing. However some of the side effects were not (yet) reported as statistically significant. With analyst price targets of 12 dollars and slew of legal class action threats that mimic the ones that IMMU had before its rapid price ascension, it is probably likely that once short sellers have covered TRVN will reach its targets. Certainly one to watch given this share weakness if one likes to use a contrarian approach. We know from StrongBio research done on the plastic surgery industry in previous articles that the industry is rapidly growing, and people don't seem to mind paying expensive prices. A more expensive but better pain killer may not be seen as a negative after all.

Kite Pharma (NASDAQ:KITE), market cap 1.8 billion, received FDA breakthrough therapy designation in December, 2015 for its refractory aggressive non Hodgkin lymphoma candidate KTE-C19. The cancer market is in the 100 billion range, so this stock should be on just about every biotechnology enthusiast's radar. At that time KITE was trading at about 75 dollars per share after a ramp up from about 50 per share earlier that fall. The price of KITE settled back to about 40 to 50 per share from January 2016 to January 2017, only recently increasing to its current 78 dollar level. KTE-C19 is therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor targeting the CD19 maker, a protein expressed on the cell surface of B cell lymphomas and leukemia. Its breakthrough designation includes treatment of diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma. Investors are optimistic due to early studies which have demonstrated 31% "curative" complete responses and remission in chemorefractory diffuse large B cell lymphoma patients after a single treatment. Analyst targets for KITE are at an average of 86 dollars per share. Timing is critical for a long position in this company, and as volatile as the share price has been over the last 2 years, anything is possible. Ironically, this stock has remained flat in spite of the volatility since breakthrough designation.

Juno pharmaceuticals (NASDAQ:JUNO) [breakthrough designation December 2016 for JCAR017 for treatment of relapsed/refractory aggressive large B-cell maladies], Novartis, (NYSE:NVS) [forPKC412 midostaurin for adults with FLT3+ AML and LEE011 combination with letrozole for treatment of HR+/HER2- advanced or metastatic breast cancer], and Bellicum pharmaceuticals (BLCM) [no breakthrough candidate] are also operating in this B cell cancer area, with emphasis being put on safety by limiting graft versus host risks of these robust anti-cancer therapies. Juno, with a 2.5 billion dollar market cap might be undervalued. Having recently discontinued development of its nicely active anti-cancer JCAR015 for ALL, due to safety issues, combined with its early FDA favor for JCAR017 plus immunosuppression regimen, and strong cash position of nearly 1 billion, one can make a good investment case on a further pullback. Immunosuppression drugs, cytokines, T-Cell, and stem cell therapies are all approaches designed to make these therapies less likely to attack healthy tissues. BLCM just raised money in an offering at 12 dollars per share, has a market cap of 330 million, and analysts average target at 27.50. StrongBio regards this option as potentially the best potential market to market cap ratio, should BLCM succeed in pulling down a share. Uniquely, BLCM technology involves modifying donor immune cells with a "kill switch" that is activated with administration of rimiducid. In an ongoing trial with 122 pediatric patients receiving partially matched donor stem cell transplants, five cases of uncontrolled graft versus host disease were resolved by the rimiducid-activated kill switch. Juno, Novartis, and Kite are good investment candidates with plenty of up-side, but the dominant market share will go to the company that best suits safety needs in graft versus host reaction. NVS is a giant with a monster market cap of 174 billion, making it more difficult to obtain a high return due to any sole candidate. So in this case perhaps riding the wing of an FDA breakthrough therapy status candidate could provide the best investment opportunity, via BLCM acquisition or stand-alone data. This creates a new category of investment candidates and fits the StrongBio contrarian outlook.

Exelixis Inc. (NASDAQ:EXEL), with a 6 billion market cap, was granted breakthrough therapy designation by FDA for renal cell carcinoma with one prior therapy. As a more mature representative of the speculative designation class, its chart reflects a little more of a steady classic upward stair than a volatile up and down nausea inducer. Since the launch of its kidney drug, Cabometyx, has grown to about 27% of the 1 billion dollar market in renal cancer. At the time of designation, it traded at about 9 dollars per share, and now trades at about 21 dollars per share 18 months later. Having made efforts to decrease its debt, and expand its pipeline, and make international partners including Takeda Pharmaceuticals in Japan, the company is stabilizing and poised for stock growth, even with its fairly large market cap. The value of stability and income can never be underappreciated, nor can a nice stepwise ascension in stock price over 100% per year.

uniQure N.V. (NASDAQ:QURE), a Dutch gene therapy company, received breakthrough therapy designation for AMT-060, its investigatory gene therapy in patients with severe hemophilia B. With a market cap of only 145 million dollars, its stock price is relatively flat since the announcement Jan 30, 2017. QURE has received regulatory approval in the European Union and carries a relatively low valuation compared to its peers, including Bluebird bio (NASDAQ:BLUE), Avalanche (AAVL), and most recently Spark Therapeutics (NASDAQ:ONCE). Briefly, gene therapy offers curative potential by inserting a gene encoding the expression of a therapeutic protein with a single administration. When a gene encoding a blood clotting protein is missing or mutated in hemophilia B patients, QURE technology introduces a copy of the proper gene to restore the presence of the clotting factor, preventing uncontrolled bleeding. Given its small market cap and high reward to risk ratio in this 10 billion full market for hemophilia, QURE could have some potential upward volatility in its future.

Tonix Pharmaceuticals (NASDAQ:TNXP) is a unique company because it received breakthrough therapy designation in December 2016 for its post-traumatic stress disorder drug candidate, TNX-02 SL. TNX-102 SL is a protective eutectic oral formulation of cyclobenzaprine that allows for a rapid systemic exposure and increased bioavailability through transmucosal delivery to modulate sleeping cycles. Scientific mechanism of action is to block serotonin receptor 2A, associated with an increase in restorative slow wave sleep and a decrease in waking after sleep onset. With a market cap around only 18 million, there would seem to be a lot of upside to this reward to risk analysis. Tonix has advanced its candidate TNX-02 SL to phase 3. But TNXP is also plagued by typical early stage biotechnology company challenges, including having recently reverse split its stock to stay listed on the Nasdaq exchange, and recently raised 8 million in capital in an offering, providing the company with approximately 30 million in operating capital. Recently TNXP enrolled its first military related post-traumatic stress disorder patient in its study. Because this stock has not made much of a move yet, some potential for upward volatility remains for TNXP stock. Because there is a likelihood of another raise of cash, StrongBio would advise caution in investing heavily in spite of the wonderful cause.

The full scope of breakthrough designation grants is beyond the scope of a Seeking Alpha article, but demonstrated is the main point that FDA breakthrough therapy designation lists yield fascinating investment candidates. Remember there are no sure things in the stock market, and that investing in biotechnology includes a lot of variability in results, risks, and volatility. Investment strategies previously published by StrongBio best include timing entries of positions, making good critical selections of key growth, and optimizing foreseeable market favor. One way to maximize the chances of an optimal result for market favor is to diversify the portfolio with companies that have obtained FDA breakthrough therapy designation, especially when perceived as undervalued. Though there are no guarantees that the market is going to reward investors short term, in the long run it appears that most breakthrough designation candidates meet with success eventually. The charts also caution that volatility may be associated with these picks. StrongBio recommends putting candidates with FDA breakthrough therapy designation on the watch list and hedge in on pullbacks.

Disclosure: I am/we are long IMMU.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: Secondary tickers include RHHBY, IMMU, ADAP, TRVN, KITE, BLCM, EXEL, JUNO, QURE, BLUE, AAVL, ONCE, TNXP but were not listed as options

Excerpt from:
Impact Of FDA Breakthrough Therapy Designation Speculative Biotechnology Stock Performance - Seeking Alpha

DSM Opens New Biotechnology Center in Delft, the Netherlands – Yahoo Finance

DELFT, the Netherlands, April 3, 2017 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials, today opens a new state-of-the-art biotechnology facility at its site in Delft to accelerate DSM's biotechnology research and development capabilities for applications in food and nutrition, feed, fuel, pharma and bio-based materials. The completion of this new biotechnology center is part of a 100 million investment program by DSM to scale up R&D in the Netherlands since 2013. The center, which offers the broadest range of biotechnology specializations under one DSM roof, clusters innovation, housing over 400 research and developments experts and builds on a solid history of nearly 150 years of fermentation and biotechnology innovation in Delft, the Netherlands.

(Logo: http://photos.prnewswire.com/prnh/20160803/395298LOGO )

The new Biotechnology Center is a further step in the development of the site in Delft, where DSM Food Specialties has its global headquarters. DSM has expanded the site in Delft over the years, including building a large, modern food and application center. DSM has also invested together with other industry players in a state-of-the-art biotech fermentation pilot plant on the Delft site. The Delft site is furthermore an important location for a number of industrial productions such as antibiotic intermediates and yeast extracts and flavors.

Feike Sijbesma, CEO/Chairman of the DSM Managing Board, commented; "DSM's new Biotechnology Center is where our scientist create solutions for societal challenges such as the need to provide all people globally with nutritious food, as well as enabling the transformation from a fossil-based to a bio-renewable-based society. DSM Biotechnology Center facilitates these needs, in an innovative environment and at an historic location in Delft where we build on nearly 150 years of scientific, academic and commercial activities."

It all started with the Nederlandsche Gist en Spiritusfabriek (Dutch Yeast and Spirits factory) in 1869. Since then, many innovations developed at the site in Delft have found their way into society including: a production strain and process for the large-scale production of penicillin which has saved millions of lives since World War II; a natural antifungal food preservative (Natamycin) which is widely used to protect a variety of foods and beverages from spoilage; and enzymes, which among other things enable the many millions of people worldwide with a lactose intolerance to include nutritious dairy in their diets. DSM's science is also behind the next generation of sustainable biofuels where the company's conversion technologies, yeast and enzymes, convert non-food cellulosic biomass into ethanol.

Innovations currently under development in the new biotechnology center include the production of fermentative steviol glycosides-the reduced-calorie, sweet-tasting molecules in the Stevia plant- as an answer to the growing global demand for sugar-reduced food and beverages. DSM's fermentation know-how helps meet this global growing demand for steviol glycosides of a high purity and reliable quality that are sustainably produced. Also, DSM scientists in the biotech center have developed a new technology that turns an inedible agricultural by-product of rapeseed, or canola, into valuable plant protein for a wide range of uses in food. These 'proteins of the future' address the increasing demand for protein globally.

The variety of specializations in DSM's biotechnology center makes it a magnet for talent. The new center employs 400 bright scientists from 27 nationalities. The biotechnology center is at the heart of the Biotech Campus Delft. Biotech Campus Delft is an initiative of DSM Delft, Delft University of Technology, the City of Delft and the Province of South Holland and builds on Delft's existing competences and internationally recognized position as a world leader in biotechnology development.

DSM's Biotechnology Center will be named the Rosalind Franklin Biotechnology Center in honor of pioneering scientist Rosalind Franklin (1920-1958), whose extraordinary work during a tragically short life and career significantly contributed to our understanding of the structure of DNA, effectively creating the basis for modern biotechnology. By honoring Rosalind Franklin, DSM pays tribute to all female heroes of science.

Read More

The official opening of the center will be performed by Louise Fresco (President Wageningen Agriculture University), Ilona Haaier (President DSM Food Specialties) and Feike Sijbesma (CEO Royal DSM).

DSM - Bright Science. Brighter Living.

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about 10billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at http://www.dsm.com.

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information: DSM Corporate Communications Andr van der Elsen tel. +31-(0)-45-5782421 e-mail media.relaties@dsm.com

DSM Food Specialties Stephen Hufton tel. +31-(0)-613-00-11-59 e-mail media.contacts@dsm.com

PRN NLD

Visit link:
DSM Opens New Biotechnology Center in Delft, the Netherlands - Yahoo Finance

Apostle Inc, a Biotechnology Company for Early Cancer Detection, is Founded in the Silicon Valley – Yahoo Finance

SUNNYVALE, Calif., April 3, 2017 /PRNewswire-iReach/ -- Three business and scientific leaders with early-stage investors today announced the formation of Apostle Inc, a biotechnology company developing a novel bioinformatics-enabled nanotechnology aimed for early cancer detection. This new approach will enable the early assessment of the cancerous signals in human peripheral blood plasma, which is believed to have a significant impact on the global healthcare landscape in both developed countries and emerging markets.

Dr. David Dongliang Ge, an experienced business and scientific leader who was President of BioSciKin Co. and Director of Bioinformatics at Gilead Sciences, will lead the new company. He is joined by two colleagues as co-founders of Apostle and his investment partners. "Biotechnologies, especially those focusing on novel diagnostic or therapeutic advancements aiming for cancer, are among the key focuses in the global economy for the next 5-20 years. By 2020, the market size ofcancerdiagnosis is estimated to reach $168.6 billion. Apostle represents one of these focuses." Dr. Ge said. "With a groundbreaking bioinformatics-enabled nanotechnology approachwe want to inform the general population that we are able to help them identify cancer signals, earlier and more accurate than conventional techniques, and potentially advise their doctors to take highly effective surgical actions. "

"It's been a great pleasure to have the opportunity to work with David and his team on this amazing venture. We're thrilled to work with this scientifically imaginative and visionary company." One of the investors said. Apostleis funded by Amino Capital, ShangBay Capital, Westlake Ventures in the Silicon Valley and a group of individual investors from both the Silicon Valley and China. Apostle is advised by Dr. Charles Cantor, an American molecular geneticist, former director of the Department of Energy Human Genome Project, a member of the National Academy of Sciences, as well as Dr. Hongyu Zhao, the Ira V. Hiscock Professor of Biostatistics and Professor of Statistics and Genetics, Chair of the Biostatistics Department and the Co-Director of Graduate Studies of the Inter-Departmental Program in Computational Biology and Bioinformatics at Yale University.

About Apostle Inc.

Apostle Inc is a biotechnology company in Sunnyvale, CA. It's in the business of the research, development, licensing, and sales of novel bioinformatics-enabled nanotechnologies and the related intellectual properties, products, and services for diagnosis and treatment of human diseases

About the founder team of Apostle Inc.

Dr. David Dongliang Geis CEO and President of Apostle. Previously, he was President of BioSciKin Co. and Simcere Diagnostics Co., two global biotechnology companies headquartered in Nanjing, China. Between 2011 and 2016, he was Director of Bioinformatics at Gilead Sciences, where he founded and provided leadership to the bioinformatics group. Dr. Ge and his group led the phylogenomic analytical support for the critical regulatory approval of Sovaldi, a world-leading anti-HCV drug. In 2014 and 2015, Dr. Ge was invited to be a member of the U.S. NHGRI Special Emphasis Panel. He was appointed as Assistant Professor of Biostatistics and Bioinformatics at Duke University School of Medicine. He received his Ph.D.ofBiostatistics and Genetic Epidemiology from Peking Union Medical College and Chinese Academy of Medical Sciences in 2004. Dr. Ge's work in discovering the IL28B genetic variants associated with the clinical treatment responses, published in Nature in 2009, has received over 3000 times of citations with the U.S. FDA's citation in its several guidance for industry. The invention was licensed to LabCorp and QuestDiagnostics,and has become clinical diagnostic services since then (LabCorp 480630 and Quest AccuType IL28).Dr. Ge has authored over 70 original articles, including 5 in Nature and 1 in Science, in total receiving over 15,000 citations. Dr. Ge was named by the U.S. Genome Technology magazine as one of the "Rising Stars" in 2009, and by the U.K. Phacilitate as one of the "Top 50 Most Influential People in Big Data" in 2015.

Read More

Bo Zhang, Ph.D.is VP of Chemistry of Apostle. Dr. Zhang received his Ph.D.ofChemistry from Stanford University in 2015 and received his B.S.ofChemistry from Peking University in 2010. Dr. Zhang has won the Gold Medal of National Chemistry Olympiad of China in 2006. Dr. Zhang has 10 years of experience in nanotechnology research, with outstanding achievements in developing novel nanomaterials with unique fluorescence characteristics. Dr. Zhang published over 30 original paperson Nature Medicine, Nature Materials, Nature Photonics, Nature Communications, etc. Dr. Zhang's two articles in Nature Medicine about novel nano-platform for type 1 diabetes and Zika virus infection diagnosis have attracted worldwide attention. Dr. Zhang has been PI for research projects funded by the NIH. He holds many patents. Dr. Zhang was the recipient of Materials Research Society Awards, Mona M. Burgess Fellow, William S. Johnson Fellowship, etc.

Xin Guo, Ph.D.is VP of Bioinformatics of Apostle. Previously, Dr. Guo was group leader at Gilead Sciences, in charge of the clinical phylogenomic program for developing Sovaldi. Dr. Guo received his Ph.D. in Computer Sciences from Duke University and M.S. in Informatics from Max Planck Institute of Germany. He received his B.S. in Informatics from Chiba Institute of Technology of Japan. Dr. Guo has over 10 years of experience in the R&D ofhigh performancecomputing, machinelearningand artificial intelligence. Dr. Guo has extensive experience in product development of complex algorithms and databases, with applications in genomic big data.

Wenqi Zeng, MD,PhD, FACMGis Chief Medical Advisor of Apostle. He is Chief Medical Officer of Simcere Diagnostics Co. Previously, Dr. Zeng was Senior Director of Molecular Genetics at Quest Diagnostics and was Director of Clinical Genomics at Ambry Genetics. Dr. Zeng was fellow of Clinical Molecular Genetics and Medical Genetics at Harvard. He received his M.D. from Xiang-Ya Medical School in China and Ph.D. in MolecularPatholgy/Molecular Genetics fromUniversityof Otago. He holds Diploma of American Board of Medical Genetics and Genomics(ABMGG),and is a qualified CAP inspection team leader, and a qualified CAP CLIA lab director in CA,FLand MD. He also has NY state COQ in molecular genetics and molecular oncology.

Media Contact: Public Relations, Apostle, Inc, Apostle, Inc, 650-483-5437, pr@apostlebio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

Originally posted here:
Apostle Inc, a Biotechnology Company for Early Cancer Detection, is Founded in the Silicon Valley - Yahoo Finance

University of Florida/Sid Martin Biotechnology Institute Receives … – PR Newswire (press release)

ALACHUA, Fla., April 3, 2017 /PRNewswire/ --Sid Martin Biotechnology Institute (SMBI), the leading biotechnology incubator at the University of Florida, has been awarded the Randall M. Whaley Incubator of the Year award for 2017, the highest award given by the International Business Innovation Association (InBIA). InBIA is the world's leading organization for advancing business incubation, acceleration and entrepreneurship. SMBI was named Incubator of the Year among more than 7,500 incubators worldwide. The annual award, sponsored by the Friends of the University Science Center in Philadelphia, recognizes the top global business incubation program and includes a cash prize.

The award was presented on March 28th at the InBIA's 31st Annual International Conference on Business Incubation. Accepting the award for SMBI were Mark S. Long, Director, and Merrie Shaw, Assistant Director. SMBI also received another award, the 2017 Technology/Science Entrepreneurship Center Program.

David L. Day, Assistant Vice President for Technology Transfer at the University of Florida, said, "We are honored for the Institute to be recognized as the best in the world incubator. It is a tribute to our staff and their outstanding efforts helping startups grow great innovations and new solutions into successful businesses that will make the world a better place."

SMBI has a biotechnology focus, and over the past 21 years has served more than 100 startup companies in biotechnology, biomedicine and bioagriculture. The Institute has created more than 2,200 high-tech jobs since its inception, and SMBI resident companies have accumulated over $1.62B in capital and M&A activity. There is a 93% survival rate for companies that entered the SMBI program since March of 2003, and an overall 78% survival rate for all companies served over the past 21 years.

Since becoming Director of SMBI in January 2016, Long has overseen the admission of 13 new companies, and the graduation of three companies. "We continue to see the growth of North Central Florida as a biotech hub," said Long. "As part of the University of Florida's Research Foundation, we are able to offer new biotechnology startups a tremendous wealth of resources, advisement and equipment. We are proud to be recognized by our peers as the top incubation program in the world."

About Sid Martin Biotechnology Institute at the University of Florida

The Sid Martin Biotechnology Institute (SMBI) is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. SMBI has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit sidmartinbio.org.

Contact:Merrie Shaw, Assistant Director, Sid Martin Biotechnology Institute, 386-462-0880, mashaw@ufl.edu, sidmartinbio.org

Related Files

Sid Martin Biotechnology Institute-Logo.png

Mark Long, Director, and Merrie Shaw, Assistant Director, Sid Martin Biotechnology Institute 2017 InBIA Awards.jpg

This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/university-of-floridasid-martin-biotechnology-institute-receives-2017-top-global-incubator-award-from-the-international-business-innovation-association-300433133.html

SOURCE Sid Martin Biotechnology Institute at the University of Florida

http://sidmartinbio.org

Read more from the original source:
University of Florida/Sid Martin Biotechnology Institute Receives ... - PR Newswire (press release)

SDSU Speaker to address topic Biotechnology: Friend or Foe in Fighting World Hunger – Farm Forum

SDSU College of Agriculture and Biological Sciences

BROOKINGS The South Dakota State University Swine Club, along with various campus organizations and industry partners, will host a presentation by Julie Borlaug on April 12 to address the controversy surrounding the use of biotechnology in food production.

Her presentation takes place at 7:00 p.m. at the Performing Arts Center on the SDSU campus.

There is no charge to attend the event, but a free-will donation of canned goods for the Brookings Food Pantry is appreciated.

As society moves farther and farther away from modern production agriculture, it creates a potential disconnect between the people who raise the food and the ones that consume it, explains Madelyn Regier, SDSU Swine Club president and an agricultural education and animal science major. The SDSU Swine Club believes that it is essential for consumers and the general public to better understand modern agriculture so we can all work together in feeding the worlds growing population in a safe and sustainable manner.

Julie Borlaug is the granddaughter of Norman E. Borlaug, known as the father of the Green Revolution. She serves as the assistant director of partnerships at the Borlaug Institute for International Agriculture at Texas A&M University.

Since the passing of her grandfather, Julie has worked to continue his legacy through developing agricultural partnerships between public, private and philanthropic groups to further the Borlaug legacy and expand upon his mission to feed the worlds hungry. She has spent her career in the nonprofit sector and has worked for organizations such as the Salvation Army and the American Cancer Society as director of development. She recently transitioned into her new role as assistant director of partnerships in order to champion her grandfathers legacy and lend a voice to his desire to create more successful collaborative partnerships between the public and private sectors in order to ensure the continuation of breakthroughs in international agriculture.

Co-sponsors of this event include the South Dakota Pork Producers Council, the SDSU College of Agriculture and Biological Sciences, the South Dakota Farm Bureau, the South Dakota Soybean Research & Promotion Council, the South Dakota Wheat Commission, and SDSU Collegiate FFA.

The SDSU Swine Club is a student-led organization dedicated to generating interest, building understanding and providing opportunities for growth in the swine industry. For more information contact Madelyn Regier, SDSU Swine Club President, at [emailprotected], or (507) 822-5944, or Swine Club Advisor Robert Thaler, professor and SDSU Extension Swine Specialist at [emailprotected], (605) 688-5435.

See more here:
SDSU Speaker to address topic Biotechnology: Friend or Foe in Fighting World Hunger - Farm Forum

Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive … – Yahoo Finance

LOS ANGELES--(BUSINESS WIRE)--

Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to patients with HER2-positive breast cancer or HER2-mutated cancers. The program will provide access to neratinib for the treatment of early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors. Patients must not be able to participate in any ongoing neratinib clinical trial to qualify for Pumas expanded access program. Puma announced a Managed Access Program for neratinib outside the United States in the fourth quarter of 2016.

The U.S. Food and Drug Administration (FDA) permits expanded access to investigational drugs for treatment use for patients with serious or immediately life-threatening diseases or conditions who do not otherwise qualify for participation in a clinical trial and lack satisfactory therapeutic alternatives.

Caligor Opco LLC, which administers the Managed Access Program for neratinib, also will manage the U.S. expanded access program by providing regulatory and logistical support.

This expanded access program reflects our commitment to make neratinib available to eligible patients who lack therapeutic treatment options, said Alan H. Auerbach, Chief Executive Officer and President of Puma. As a specialist firm that focuses on early access to medicines, Caligor will facilitate access to neratinib for patients who may benefit from this therapy.

About the Neratinib Expanded Access Program

The neratinib EAP is a program for U.S. patients with early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors. This EAP is being administered on behalf of Puma by Caligor Opco LLC. U.S. healthcare professionals seeking more information about the neratinib EAP can email neratinibUS@caligorrx.com for additional information. Patients who are interested in enrolling in the neratinib EAP should speak with their physician to determine if neratinib is an appropriate option. Neratinib is an investigational agent and, as such, has not been approved by the FDA or any other regulatory agencies in any markets.

About Caligor

Caligor Opco LLC, a portfolio company of Diversis Capital, LLC, is a global company that manages the regulatory, logistics and supply chain needs for global access programs as well as the sourcing, storing and distribution of comparator drugs for clinical trials. Caligors global access programs help to meet the medical needs of patients worldwide by providing access to medicines in situations where the drug has not yet been approved, or is otherwise commercially unavailable. In addition, through its proprietary TrialAssist program, Caligor optimizes its services by providing for labeling, QP certification, storage, distribution and destruction of clinical trial and unlicensed medicines managed in the access programs. The company serves pharmaceutical and biotechnology companies from facilities in Secaucus, New Jersey and Dartford, UK, as well as strategically situated depot locations worldwide. More information is available at http://caligorrx.com.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidatesPB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the development of the oral version of neratinib, and its most advanced drug candidates are directed at the treatment of HER2-positive breast cancer. The Company believes that neratinib has clinical application in the treatment of several other cancers as well, including non-small cell lung cancer and other tumor types that over-express or have a mutation in HER2.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

Read More

Forward-Looking Statements:

This press release contains forward-looking statements, including statements regarding the expanded access program for PB272 (neratinib) for the treatment of early stage HER2-positive breast cancer (extended adjuvant setting), HER2-positive metastatic breast cancer and HER2-mutated solid tumors. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has no product revenue and no products approved for marketing; the Companys dependence on PB272, which is still under development and may never receive regulatory approval; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Companys drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Companys products; the Companys reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; the Companys dependence on licensed intellectual property; and the other risk factors disclosed in the periodic reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Annual Report on Form 10-K for the year ended December 31, 2016. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170402005071/en/

See the original post:
Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive ... - Yahoo Finance

Industry Analysis: Should You Buy Halozyme Therapeutics, Inc. (HALO) in Biotechnology? – InvestorsObserver

The 65 rating InvestorsObserver gives to Halozyme Therapeutics, Inc. (HALO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 73 percent of stocks in the Biotechnology industry, HALOs 65 overall rating means the stock scores better than 65 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 65 means the stock is more attractive than 65 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Halozyme Therapeutics, Inc. (HALO) stock is trading at $16.32 as of 11:17 AM on Friday, Mar 20, an increase of $1.42, or 9.53% from the previous closing price of $14.90. The stock has traded between $14.59 and $17.07 so far today. Volume today is below average. So far 1,323,518 shares have traded compared to average volume of 2,074,179 shares.

To see the top 5 stocks in Biotechnology click here.

See more here:
Industry Analysis: Should You Buy Halozyme Therapeutics, Inc. (HALO) in Biotechnology? - InvestorsObserver

Prana Biotechnology and Xenetic Biosciences Expand Their … – Yahoo Finance

NEW YORK, NY / ACCESSWIRE / March 31, 2017 / Prana Biotechnology and Xenetic Biosciences both saw their company's stock prices soar on news of a broader, more global product distribution. Prana is continuing to expand its presentation of PBT-434, while Xenetic is moving ahead with its strategic planning goals to make its product technology available to a larger geographical area.

RDI Initiates Coverage:

Prana Biotechnology Limited https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences Inc. https://ub.rdinvesting.com/news/?ticker=XBIO

Prana Biotechnology advanced 37.65% to close at $3.40 on Thursday. The stock traded in a wide range between $4.58 and $2.75 during the day on a volume of 11.95 million shares traded. The company has presented new data from its Reach2HD trial at the American Neurological Association Annual Meeting held in Baltimore. Its primary candidate drug, PBT-434, demonstrated pre-clinical evidence that the drug will help with the treatment of movement disorders of patients with Parkinson's Disease.

Prana Biotechnology, an Australian company, for the half-year period ending December 31, 2016, reported total operating expenses of $6.05 million AUD, a pre-tax income of $3.65 million AUD, and a loss of $0.68 AUD per share.

Access RDI's Prana Biotechnology Research Report at: https://ub.rdinvesting.com/news/?ticker=PRAN

Xenetic Biosciences accelerated to advance 44.30% to close at $5.44 on Thursday. The stock traded between $5.61 and $3.87 on volume of 180,793 shares traded. Xenetic has been aggressively promoting its products internationally, and the rise in price is due in part to it becoming a member of the NASDAQ community on March 30th. The company has been expanding its patent portfolio to a number of countries, including Europe and the United States. Currently, their major marketable product is PolyXen technology platform. The product's IP on its PolyXen technology platform will afford protection on average for the next 10 to 12 years.

The latest financial report with period ending September 30, 2016, showed the company posting $2.25 million in operating expenses, a net loss of $2.47 million, and net loss per share of $0.28 and it had about $212,000 of cash assets on its books as on September 30th.

Access RDI's Xenetic Biosciences Research Report at: https://ub.rdinvesting.com/news/?ticker=XBIO

Our Actionable Research on Prana Biotechnology Limited (NASDAQ: PRAN) and Xenetic Biosciences Inc. (NASDAQ: XBIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at http://www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA and Chartered Financial Analyst are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

Read this article:
Prana Biotechnology and Xenetic Biosciences Expand Their ... - Yahoo Finance

Benefits & Risks of Biotechnology – Future of Life Institute

This is a whole new era where were moving beyond little edits on single genes to being able to write whatever we want throughout the genome.

-George Church, Professor of Genetics at Harvard Medical School

Click here to see this page in other languages:JapaneseRussian

How are scientists putting natures machinery to use for the good of humanity, and how could things go wrong?

Biotechnology is nearly as old as humanity itself. The food you eat and the pets you love? You can thank our distant ancestors for kickstarting the agricultural revolution, using artificial selection for crops, livestock, and other domesticated animals. When Edward Jenner invented vaccines and when Alexander Fleming discovered antibiotics, they were harnessing the power of biotechnology. And, of course, modern civilization would hardly be imaginable without the fermentation processes that gave us beer, wine, and cheese!

When he coined the term in 1919, the agriculturalist Karl Ereky described biotechnology as all lines of work by which products are produced from raw materials with the aid of living things. In modern biotechnology, researchers modify DNA and proteins to shape the capabilities of living cells, plants, and animals into something useful for humans. Biotechnologists do this by sequencing, or reading, the DNA found in nature, and then manipulating it in a test tube or, more recently, inside of living cells.

In fact, the most exciting biotechnology advances of recent times are occurring at the microscopic level (and smaller!) within the membranes of cells. After decades of basic research into decoding the chemical and genetic makeup of cells, biologists in the mid-20th century launched what would become a multi-decade flurry of research and breakthroughs. Their work has brought us the powerful cellular tools at biotechnologists disposal today. In the coming decades, scientists will use the tools of biotechnology to manipulate cells with increasing control, from precision editing of DNA to synthesizing entire genomes from their basic chemical building blocks. These cells could go on to become bomb-sniffing plants, miracle cancer drugs, or de-extincted wooly mammoths. And biotechnology may be a crucial ally in the fight against climate change.

But rewriting the blueprints of life carries an enormous risk. To begin with, the same technology being used to extend our lives could instead be used to end them. While researchers might see the engineering of a supercharged flu virus as a perfectly reasonable way to better understand and thus fight the flu, the public might see the drawbacks as equally obvious: the virus could escape, or someone could weaponize the research. And the advanced genetic tools that some are considering for mosquito control could have unforeseen effects, possibly leading to environmental damage. The most sophisticated biotechnology may be no match for Murphys Law.

While the risks of biotechnology have been fretted over for decades, the increasing pace of progress from low cost DNA sequencing to rapid gene synthesis to precision genome editing suggests biotechnology is entering a new realm of maturity regarding both beneficial applications and more worrisome risks. Adding to concerns, DIY scientists are increasingly taking biotech tools outside of the lab. For now, many of the benefits of biotechnology are concrete while many of the risks remain hypotheticals, but it is better to be proactive and cognizant of the risks than to wait for something to go wrong first and then attempt to address the damage.

Satellite images make clear the massive changes that mankind has made to the surface of the Earth: cleared forests, massive dams and reservoirs, millions of miles of roads. If we could take satellite-type images of the microscopic world, the impact of biotechnology would be no less obvious. The majority of the food we eat comes from engineered plants, which are modified either via modern technology or by more traditional artificial selection to grow without pesticides, to require fewer nutrients, or to withstand the rapidly changing climate. Manufacturers have substituted petroleum-based ingredients with biomaterials in many consumer goods, such as plastics, cosmetics, and fuels. Your laundry detergent? It almost certainly contains biotechnology. So do nearly all of your cotton clothes.

But perhaps the biggest application of biotechnology is in human health. Biotechnology is present in our lives before were even born, from fertility assistance to prenatal screening to the home pregnancy test. It follows us through childhood, with immunizations and antibiotics, both of which have drastically improved life expectancy. Biotechnology is behind blockbuster drugs for treating cancer and heart disease, and its being deployed in cutting-edge research to cure Alzheimers and reverse aging. The scientists behind the technology called CRISPR/Cas9 believe it may be the key to safely editing DNA for curing genetic disease. And one company is betting that organ transplant waiting lists can be eliminated by growing human organs in chimeric pigs.

Along with excitement, the rapid progress of research has also raised questions about the consequences of biotechnology advances. Biotechnology may carry more risk than other scientific fields: microbes are tiny and difficult to detect, but the dangers are potentially vast. Further, engineered cells could divide on their own and spread in the wild, with the possibility of far-reaching consequences. Biotechnology could most likely prove harmful either through the unintended consequences of benevolent research or from the purposeful manipulation of biology to cause harm. One could also imagine messy controversies, in which one group engages in an application for biotechnology that others consider dangerous or unethical.

Sugarcane farmers in Australia in the 1930s had a problem: cane beetles were destroying their crop. So, they reasoned that importing a natural predator, the cane toad, could be a natural form of pest control. What could go wrong? Well, the toads became a major nuisance themselves, spreading across the continent and eating the local fauna (except for, ironically, the cane beetle).

While modern biotechnology solutions to societys problems seem much more sophisticated than airdropping amphibians into Australia, this story should serve as a cautionary tale. To avoid blundering into disaster, the errors of the past should be acknowledged.

The world recently witnessed the devastating effects of disease outbreaks, in the form of Ebola and the Zika virus but those were natural in origin. The malicious use of biotechnology could mean that future outbreaks are started on purpose. Whether the perpetrator is a state actor or a terrorist group, the development and release of a bioweapon, such as a poison or infectious disease, would be hard to detect and even harder to stop. Unlike a bullet or a bomb, deadly cells could continue to spread long after being deployed. The US government takes this threat very seriously, and the threat of bioweapons to the environment should not be taken lightly either.

Developed nations, and even impoverished ones, have the resources and know-how to produce bioweapons. For example, North Korea is rumored to have assembled an arsenal containing anthrax, botulism, hemorrhagic fever, plague, smallpox, typhoid, and yellow fever, ready in case of attack. Its not unreasonable to assume that terrorists or other groups are trying to get their hands on bioweapons as well. Indeed, numerous instances of chemical or biological weapon use have been recorded, including the anthrax scare shortly after 9/11, which left 5 dead after the toxic cells were sent through the mail. And new gene editing technologies are increasing the odds that a hypothetical bioweapon targeted at a certain ethnicity, or even a single individual like a world leader, could one day become a reality.

While attacks using traditional weapons may require much less expertise, the dangers of bioweapons should not be ignored. It might seem impossible to make bioweapons without plenty of expensive materials and scientific knowledge, but recent advances in biotechnology may make it even easier for bioweapons to be produced outside of a specialized research lab. The cost to chemically manufacture strands of DNA is falling rapidly, meaning it may one day be affordable to print deadly proteins or cells at home. And the openness of science publishing, which has been crucial to our rapid research advances, also means that anyone can freely Google the chemical details of deadly neurotoxins. In fact, the most controversial aspect of the supercharged influenza case was not that the experiments had been carried out, but that the researchers wanted to openly share the details.

On a more hopeful note, scientific advances may allow researchers to find solutions to biotechnology threats as quickly as they arise. Recombinant DNA and biotechnology tools have enabled the rapid invention of new vaccines which could protect against new outbreaks, natural or man-made. For example, less than 5 months after the World Health Organization declared Zika virus a public health emergency, researchers got approval to enroll patients in trials for a DNA vaccine.

Biotechnology doesnt have to be deadly, or even dangerous, to fundamentally change our lives. While humans have been altering genes of plants and animals for millennia first through selective breeding and more recently with molecular tools and chimeras we are only just beginning to make changes to our own genomes (amid great controversy).

Cutting-edge tools like CRISPR/Cas9 and DNA synthesis raise important ethical questions that are increasingly urgent to answer. Some question whether altering human genes means playing God, and if so, whether we should do that at all. For instance, if gene therapy in humans is acceptable to cure disease, where do you draw the line? Among disease-associated gene mutations, some come with virtual certainty of premature death, while others put you at higher risk for something like Alzheimers, but dont guarantee youll get the disease. Many others lie somewhere in between. How do we determine a hard limit for which gene surgery to undertake, and under what circumstances, especially given that the surgery itself comes with the risk of causing genetic damage? Scholars and policymakers have wrestled with these questions for many years, and there is some guidance in documents such as the United Nations Universal Declaration on the Human Genome and Human Rights.

And what about ways that biotechnology may contribute to inequality in society? Early work in gene surgery will no doubt be expensive for example, Novartis plans to charge $475,000 for a one-time treatment of their recently approved cancer therapy, a drug which, in trials, has rescued patients facing certain death. Will todays income inequality, combined with biotechnology tools and talk of designer babies, lead to tomorrows permanent underclass of people who couldnt afford genetic enhancement?

Advances in biotechnology are escalating the debate, from questions about altering life to creating it from scratch. For example, a recently announced initiative called GP-Write has the goal of synthesizing an entire human genome from chemical building blocks within the next 10 years. The project organizers have many applications in mind, from bringing back wooly mammoths to growing human organs in pigs. But, as critics pointed out, the technology could make it possible to produce children with no biological parents, or to recreate the genome of another human, like making cellular replicas of Einstein. To create a human genome from scratch would be an enormous moral gesture, write two bioethicists regarding the GP-Write project. In response, the organizers of GP-Write insist that they welcome a vigorous ethical debate, and have no intention of turning synthetic cells into living humans. But this doesnt guarantee that rapidly advancing technology wont be applied in the future in ways we cant yet predict.

Its nearly impossible to imagine modern biotechnology without DNA sequencing. Since virtually all of biology centers around the instructions contained in DNA, biotechnologists who hope to modify the properties of cells, plants, and animals must speak the same molecular language. DNA is made up of four building blocks, or bases, and DNA sequencing is the process of determining the order of those bases in a strand of DNA. Since the publication of the complete human genome in 2003, the cost of DNA sequencing has dropped dramatically, making it a simple and widespread research tool.

Benefits: Sonia Vallabh had just graduated from law school when her mother died from a rare and fatal genetic disease. DNA sequencing showed that Sonia carried the fatal mutation as well. But far from resigning to her fate, Sonia and her husband Eric decided to fight back, and today they are graduate students at Harvard, racing to find a cure. DNA sequencing has also allowed Sonia to become pregnant, since doctors could test her eggs for ones that dont have the mutation. While most peoples genetic blueprints dont contain deadly mysteries, our health is increasingly supported by the medical breakthroughs that DNA sequencing has enabled. For example, researchers were able to track the 2014 Ebola epidemic in real time using DNA sequencing. And pharmaceutical companies are designing new anti-cancer drugs targeted to people with a specific DNA mutation. Entire new fields, such as personalized medicine, owe their existence to DNA sequencing technology.

Risks: Simply reading DNA is not harmful, but it is foundational for all of modern biotechnology. As the saying goes, knowledge is power, and the misuse of DNA information could have dire consequences. While DNA sequencing alone cannot make bioweapons, its hard to imagine waging biological warfare without being able to analyze the genes of infectious or deadly cells or viruses. And although ones own DNA information has traditionally been considered personal and private, containing information about your ancestors, family, and medical conditions, governments and corporations increasingly include a persons DNA signature in the information they collect. Some warn that such databases could be used to track people or discriminate on the basis of private medical records a dystopian vision of the future familiar to anyone whos seen the movie GATTACA. Even supplying patients with their own genetic information has come under scrutiny, if its done without proper context, as evidenced by the dispute between the FDA and the direct-to-consumer genetic testing service 23andMe. Finally, DNA testing opens the door to sticky ethical questions, such as whether to carry to term a pregnancy after the fetus is found to have a genetic mutation.

The modern field of biotechnology was born when scientists first manipulated or recombined DNA in a test tube, and today almost all aspects of society are impacted by so-called rDNA. Recombinant DNA tools allow researchers to choose a protein they think may be important for health or industry, and then remove that protein from its original context. Once removed, the protein can be studied in a species thats simple to manipulate, such as E. coli bacteria. This lets researchers reproduce it in vast quantities, engineer it for improved properties, and/or transplant it into a new species. Modern biomedical research, many best-selling drugs, most of the clothes you wear, and many of the foods you eat rely on rDNA biotechnology.

Benefits: Simply put, our world has been reshaped by rDNA. Modern medical advances are unimaginable without the ability to study cells and proteins with rDNA and the tools used to make it, such as PCR, which helps researchers copy and paste DNA in a test tube. An increasing number of vaccines and drugs are the direct products of rDNA. For example, nearly all insulin used in treating diabetes today is produced recombinantly. Additionally, cheese lovers may be interested to know that rDNA provides ingredients for a majority of hard cheeses produced in the West. Many important crops have been genetically modified to produce higher yields, withstand environmental stress, or grow without pesticides. Facing the unprecedented threats of climate change, many researchers believe rDNA and GMOs will be crucial in humanitys efforts to adapt to rapid environmental changes.

Risks: The inventors of rDNA themselves warned the public and their colleagues about the dangers of this technology. For example, they feared that rDNA derived from drug-resistant bacteria could escape from the lab, threatening the public with infectious superbugs. And recombinant viruses, useful for introducing genes into cells in a petri dish, might instead infect the human researchers. Some of the initial fears were allayed when scientists realized that genetic modification is much trickier than initially thought, and once the realistic threats were identified like recombinant viruses or the handling of deadly toxins safety and regulatory measures were put in place. Still, there are concerns that rogue scientists or bioterrorists could produce weapons with rDNA. For instance, it took researchers just 3 years to make poliovirus from scratch in 2006, and today the same could be accomplished in a matter of weeks. Recent flu epidemics have killed over 200,000, and the malicious release of an engineered virus could be much deadlier especially if preventative measures, such as vaccine stockpiles, are not in place.

Synthesizing DNA has the advantage of offering total researcher control over the final product. With many of the mysteries of DNA still unsolved, some scientists believe the only way to truly understand the genome is to make one from its basic building blocks. Building DNA from scratch has traditionally been too expensive and inefficient to be very practical, but in 2010, researchers did just that, completely synthesizing the genome of a bacteria and injecting it into a living cell. Since then, scientists have made bigger and bigger genomes, and recently, the GP-Write project launched with the intention of tackling perhaps the ultimate goal: chemically fabricating an entire human genome. Meeting this goal and within a 10 year timeline will require new technology and an explosion in manufacturing capacity. But the projects success could signal the impact of synthetic DNA on the future of biotechnology.

Benefits: Plummeting costs and technical advances have made the goal of total genome synthesis seem much more immediate. Scientists hope these advances, and the insights they enable, will ultimately make it easier to make custom cells to serve as medicines or even bomb-sniffing plants. Fantastical applications of DNA synthesis include human cells that are immune to all viruses or DNA-based data storage. Prof. George Church of Harvard has proposed using DNA synthesis technology to de-extinct the passenger pigeon, wooly mammoth, or even Neanderthals. One company hopes to edit pig cells using DNA synthesis technology so that their organs can be transplanted into humans. And DNA is an efficient option for storing data, as researchers recently demonstrated when they stored a movie file in the genome of a cell.

Risks: DNA synthesis has sparked significant controversy and ethical concerns. For example, when the GP-Write project was announced, some criticized the organizers for the troubling possibilities that synthesizing genomes could evoke, likening it to playing God. Would it be ethical, for instance, to synthesize Einsteins genome and transplant it into cells? The technology to do so does not yet exist, and GP-Write leaders have backed away from making human genomes in living cells, but some are still demanding that the ethical debate happen well in advance of the technologys arrival. Additionally, cheap DNA synthesis could one day democratize the ability to make bioweapons or other nuisances, as one virologist demonstrated when he made the horsepox virus (related to the virus that causes smallpox) with DNA he ordered over the Internet. (It should be noted, however, that the other ingredients needed to make the horsepox virus are specialized equipment and deep technical expertise.)

Many diseases have a basis in our DNA, and until recently, doctors had very few tools to address the root causes. That appears to have changed with the recent discovery of a DNA editing system called CRISPR/Cas9. (A note on terminology CRISPR is a bacterial immune system, while Cas9 is one protein component of that system, but both terms are often used to refer to the protein.) It operates in cells like a DNA scissor, opening slots in the genome where scientists can insert their own sequence. While the capability of cutting DNA wasnt unprecedented, Cas9 dusts the competition with its effectiveness and ease of use. Even though its a biotech newcomer, much of the scientific community has already caught CRISPR-fever, and biotech companies are racing to turn genome editing tools into the next blockbuster pharmaceutical.

Benefits: Genome editing may be the key to solving currently intractable genetic diseases such as cystic fibrosis, which is caused by a single genetic defect. If Cas9 can somehow be inserted into a patients cells, it could fix the mutations that cause such diseases, offering a permanent cure. Even diseases caused by many mutations, like cancer, or caused by a virus, like HIV/AIDS, could be treated using genome editing. Just recently, an FDA panel recommended a gene therapy for cancer, which showed dramatic responses for patients who had exhausted every other treatment. Genome editing tools are also used to make lab models of diseases, cells that store memories, and tools that can detect epidemic viruses like Zika or Ebola. And as described above, if a gene drive, which uses Cas9, is deployed effectively, we could eliminate diseases such as malaria, which kills nearly half a million people each year.

Risks: Cas9 has generated nearly as much controversy as it has excitement, because genome editing carries both safety issues and ethical risks. Cutting and repairing a cells DNA is not risk-free, and errors in the process could make a disease worse, not better. Genome editing in reproductive cells, such as sperm or eggs, could result in heritable genetic changes, meaning dangerous mutations could be passed down to future generations. And some warn of unethical uses of genome editing, fearing a rise of designer babies if parents are allowed to choose their childrens traits, even though there are currently no straightforward links between ones genes and their intelligence, appearance, etc. Similarly, a gene drive, despite possibly minimizing the spread of certain diseases, has the potential to create great harm since it is intended to kill or modify an entire species. A successful gene drive could have unintended ecological impacts, be used with malicious intent, or mutate in unexpected ways. Finally, while the capability doesnt currently exist, its not out of the realm of possibility that a rogue agent could develop genetically selective bioweapons to target individuals or populations with certain genetic traits.

Videos

Research Papers

Books

Informational Documents

Articles

Organizations

The organizations above all work on biotechnology issues, though many cover other topics as well. This list is undoubtedly incomplete; please contact us to suggest additions or corrections.

Special thanks to Jeff Bessen for his help researching and writing this page.

Here is the original post:
Benefits & Risks of Biotechnology - Future of Life Institute

Boston funding news: Biotechnology and healthcare top recent local investments – Hoodline

Boston-based pharmaceutical company AZTherapies, Inc. has secured $26 million in Series C funding, according to company database Crunchbase, topping the citys recent funding headlines. The cash infusion was announced Oct. 18 and led by Cosine.

According to its Crunchbase profile, "AZTherapies is an advanced clinical-stage biopharmaceutical company developing novel therapies that aim to fundamentally change neurodegenerative disease progression, extending normal cognition and function and improving quality of life in the aging population."

The nine-year-old company has raised four previous funding rounds, including a $6.5 million convertible note round in 2017.

The round brings total funding raised by Boston companies in biotechnology over the past 90 days to $414 million, an increase of $308 million from the previous three-month period. The local biotechnology industry has seen 38 funding rounds over the past year, raking in a total of $1.3 billion in venture funding.

In other local funding news, blockchain company Oneiro announced a $5 million Series A funding round on Oct. 2, financed by COSIMO Ventures.

According to Crunchbase, "Oneiro is focused on developing technologies around decentralized, secure and dependable cryptocurrency. Blockchain technology has enabled the use and management of digital currencies worldwide, and Oneiro is positioning its technology to be an integral part of the markets future."

The company also raised a $3 million seed round in 2018.

Meanwhile, video games company Mightier raised $250,000 in corporate round funding, announced on Sept. 24. The round was financed by Modern Times Group (MTG).

From the company's Crunchbase profile, "Mightier helps children build emotional strength. Our program, developed at Harvard Medical School, aims to help children with behavioral and emotional challenges learn how to harness emotions in daily life."

Mightier last raised $6.6 million in Series A funding earlier this year.

Also of note, database and cloud storage company Wasabi Technologies raised funding, announced on Sept. 29 and financed by NTT DOCOMO Ventures.

From Crunchbase, "Wasabi is the hot cloud storage company. Hot storage is fast to write, low-cost and reliable cloud storage."

The company previously raised Series B funding in 2018.

This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.

See original here:
Boston funding news: Biotechnology and healthcare top recent local investments - Hoodline

StemRx Biosciences joins hands with Amity Institute of Biotechnology – BSI bureau

Helping people to tackle a number of ailments is the main aim of this collaboration

To help people get rid of various fatal diseases, StemRx Bioscience Solutions Pvt. Ltd., in association with Amity Institute of Biotechnology, Navi Mumbai, organized a one day International seminar on how technologies like Tissue Nanotransfection, bone marrow transplant, organ transplant, and umbilical cord blood transplantation can change the future course of various diseases like cancer.

Along with Dr. Pradeep Mahajan, many other dignitaries like Dr. Chandan K. Sen, Director, Indian Center for Regenerative Medicine and Engineering , Indiana University, USA; Dr. M. Gopinath, Principal Scientist, CFTRI, Mysore; Dr. Satyandra Katewa, Head, Department of Paediatric Hematology-Oncology and Bone Marrow Transplant, Jaipur; Dr. Sunali Khanna, Nair Hospital, Mumbai; Dr. Deepa Bhartiya, Senior Scientific Officer, NIRRH, Mumbai, and Dr. Neetin Desai, Director, Amity Institute Of Biotechnology were part of the workshop.

Today, the Indian healthcare sector is growing at a brisk pace. With the help of advanced medical technologies, it is now possible to treat diseases with efficacy. The technological advancements are changing the very face of medicine. Thus, to help people tackle a number of ailments StemRx Biosciences Solutions Pvt. Ltd tied up with Amity Institute of Biotechnology, Navi Mumbai.

Dr. Pradeep Mahajan, Regenerative Medicine Researcher, Mumbai explained, The seminar highlighted how technologies like Tissue Nanotransfection, bone marrow, transplant, organ transplant, and umbilical cord blood transplantation can help treat various diseases like cancer, and infertility. I conducted a session on how new age medicine, regenerative medicine, and cell-based therapy can be a good option for people to tackle cancer, autoimmune diseases, urinary problems, neurological disorders, spinal cord injuries, and weak immune systems. Cell-based therapy can solve the majority of diseases without having conflicts.The newest technology Tissue Nanotransfection is going to create a revolution in cell-based therapy. I am honored, proud, and will look forward to many more associations with Amity in the near future.

More than 300 participants including the students, gynecologists, and government authorities were present for the seminar.

See more here:
StemRx Biosciences joins hands with Amity Institute of Biotechnology - BSI bureau

Biotechnology Facts – Softschools.com

Biotechnology is not a new field, although its intentional use is comparatively new. Humans have unknowingly used biotechnology practices for thousands of years, specifically in farming and pharmaceuticals. Even in the Neolithic period, early humans incorporated a very broad definition of biotechnology in their newfound agricultural attempts. By the broad definition of the field, early civilizations' brewing and fermenting of alcohol, specifically by the Egyptians, Chinese, and Indians, and the use of yeast in bread making by many civilizations would fall under biotechnology. The term "biotechnology" is thought to have been first used in 1919 by Karoly Ereky. As new practices in biotechnology occur, additional subfields of the science have been created, including genomics, gene therapy, immunology, and more. By some standards, early practices in farming that utilized selective breeding could also be considered biotechnology. Perhaps the most crucial application of biotechnology of its era was the production of antibiotics to fight infection. Even today, researchers are continuing to improve upon biofuels in order to cut down on fossil fuel mining and greenhouse gas emissions. There are four major areas of biotechnology study and application. These are medical, agriculture, non-food agriculture, and environmental applications. While pharmaceuticals like antibiotics, insulin, and vaccines can be considered biotechnology uses, innovations like gene therapy and gene suppression would also meet that definition. Non-food agriculture uses apply to things like the creation of plants to produce plastics, and enzymes or single-celled organisms for industrial fermentation and the production of textiles. Some environmental applications of biotechnology include uses microbes to clean up an oil spill or fungal or algae outbreak. Through the efforts of the US Congress and the National Institute of General Medical Sciences under the National Institutes of Health, biotechnology has become a sought-after field of study in many major universities. Biotechnology does have its critics, as there is currently a movement to ban and avoid genetically modified foods grown through genetically altered agriculture. A labeling system was implemented in the US that requires genetically altered produce to be labeled as such.

The rest is here:
Biotechnology Facts - Softschools.com

Biotechnology – tnstate.edu

Department Chair:Dr. Samuel Nahashon, (615) 963-5431

Suggested Four-year Plan

17

16

16

16

14

14

14

13

For the BS degree, in addition to the General Education requirements of the university, students in the Biotechnology Concentration take the following courses:

NumberCourse TitleUNIV 1000 OrientationAGSC 1200 Introduction to Plant ScienceAGSC 1410 Introduction to Animal ScienceAGSC 2010 Introduction to AgribusinessAGSC 2200 Fundamentals of Soil ScienceAGSC 2410 Introduction to Poultry ScienceAGSC 3540 Laboratory instrumentationAGSC 4500 Senior ProjectAGSC 4710-4720 SeminarAGSC xxxx Biotechnology and SocietyAGSC xxxx Principals and Methods of Biotechnology IAGSC xxxx Principals and Methods of Biotechnology IIAGSC xxxx Biotechnology in Agricultural ProductionAGSC xxxx Agricultural Bio-securityAGSC xxxx Ethics and Bio-forensics in Ag. BiotechnologyBIOL 4112 BioinformaticsBIOL 1110-1 General Biology I & LabCHEM 2010 Organic Chemistry I & LabBIOL 2110 Cell Biology + LabBIOL 2120, 2121 Genetics + LabCHEM 3410 General Biochemistry I & LabBIOL 3410 Principles General BacteriologBIOL 4110, 4111 Molecular Genetics & Lab

And two credits of electives from the following list:

NumberCourse Title AGSC 3210 Principles of Crop ScienceAGSC 3260 Plant PhysiologyAGSC 3300 Plant PathologyAGSC 3320 Propagation of Horticultural PlantsAGSC 3400 Animal and Plant GeneticsAGSC 3410 Anatomy and Physiology of Domestic AnimalsAGSC 3430 Animal Health and Disease PreventionAGSC 3530 Food MicrobiologyAGSC 4070 Agricultural Special ProblemsAGSC 4310 Plant BreedingAGSC 4410 Dairy Production and ManagementAGSC 4420 Poultry Disease Prevention and SanitationAGSC 4430 Animal NutritionAGSC 4440 Physiology of Reproduction

For additional information:ContactDr. S. Nahashon.

The Ph.D. concentration in Biotechnology is an interdepartmental degree program that is jointly offered by the Department of Agricultural Sciences and theDepartment of Biological Sciences.

Admission Requirements: Ph.D. Program

Administered by the Department of Biological Sciences. Applicants to the Ph.D. program must submit a completed application form, a personal statement describing interest in the program and professional goals, and three letters of recommendations from persons familiar with the applicant's academic work, especially in biology. The departmental admissions committee will base admission upon these materials and interviews with selected applicants.

Admission requires the applicant have a bachelor's degree from a fully accredited four-year college or university, a minimum score of 1370 calculated from the GPA multiplied by 200 and added to the GRE combined verbal and quantitative scores and a minimum score of 600 on the GRE subject test in biology. Students may also be admitted with subject test scores below 600, but such students must take the departmental diagnostic examination. The admissions committee will evaluate the student's performance on the examination and design a curriculum to eliminate any identified weaknesses. After passing the recommended courses with a grade of "B" or better in each, the student will begin the Ph.D. curriculum.

Programs of Study: Ph.D. Program

The degree candidate must file a program of study after competing nine (9) semester hours of graduate work, but before completing fifteen (15) hours of graduate work. The program lists the courses which will be used to satisfy degree requirements, as well as detailing how other requirements will be met. The student may later change the program of study with the written approval of the Department and the Graduate School.

Admission to Candidacy: Ph.D. Program

The student must apply for admission to candidacy after completing the 24 hour core of required courses (See Degree Requirements below), with an average of "B" (3.00) or better, passing the comprehensive examination, and gaining approval of the dissertation proposal. Students may have a "C" grade in no more than two courses (6 credit hours), neither of which can be a core course. No "D" or "F" grades are acceptable. A student who receives a grade of "C" in excess of six credits must repeat the course and achieve at least a "B".

Degree Requirements: Ph.D. Program

After gaining admission to candidacy, the student must complete an approved curriculum (24 hours minimum of electives set by the student's research advisory committee), enroll in Graduate Seminar (BIOL 7010, 7020), complete a dissertation (24 hours), and successfully defend the dissertation prior to gaining the Ph.D. degree (please refer to Biological Sciences Graduate Student Handbook for specific dissertation requirements). A student entering with a Master's degree may have applicable hours transferred toward the Ph.D. program, as determined by the Advisory Committee. The total number of hours required is 76.

For additional information:ContactDr. S. Nahashon.

Graduate Elective Courses

AGSC 5160 Animal Genetics and BreedingAGSC 5190 Plant BreedingAGSC 7010 Advancements in Agricultural BiotechnologyAGSC 7020 Economic, Regulatory and Ethical Issues in BiotechnologyAGSC 7030 Gene Expression and Regulation and Regulation in Higher PlantsAGSC 7040 Plant Tissue Culture Methods and ApplicationsAGSC 7050 Biotechnology in Animal ReproductionAGSC 7060 Advanced Soil TechnologyAGSC 7070 Molecular Genetic Ecology

Original post:
Biotechnology - tnstate.edu

Puma Biotechnology FDA Live Blog – Forbes


Forbes
Puma Biotechnology FDA Live Blog
Forbes
This is a live blog of the meeting of the Food and Drug Administration's meeting regarding neratinib, a breast cancer drug being developed by Puma Biotechnology. The basic questions to be addressed, per my story from Monday. Puma's not applying to sell ...
Why Puma Biotechnology Inc Jumped Higher TodayMotley Fool
Puma Biotechnology Receives FDA Advisory Committee Support for NeratinibBusiness Wire (press release)
Puma Biotechnology (PBYI) PT Raised to $86 at BofA/Merrill LynchStreetInsider.com
ExpertGazette -Equities.com -Finance News Daily -Zacks
all 71 news articles »

Follow this link:
Puma Biotechnology FDA Live Blog - Forbes